OptiBiotix Health PLC Launch of LeanBiome with global nutrition leader (1039U)
01 Diciembre 2021 - 12:59AM
UK Regulatory
TIDMOPTI
RNS Number : 1039U
OptiBiotix Health PLC
01 December 2021
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Launch of LeanBiome (TM) with global leader in beauty &
nutrition brands
OptiBiotix Health plc (AIM: OPTI), announces the launch of a new
sports nutrition product range branded LeanBiome (TM) alongside a
new supply & licensing agreement with a leading global player
in beauty & nutrition ("the Partner"). This agreement grants
the Partner a license to manufacture and sell finished products
containing LeanBiome (TM) across Europe, Australia and Asia.
OptiBiotix is a life sciences business developing patented
science and human study-based compounds that modulate the
microbiome to address metabolic syndrome and diabetes, systemic
low-grade inflammation, obesity, cardiovascular disease, high
cholesterol and supports healthy aging.
The Partner is a British e-commerce company which specialises in
taking beauty and nutrition brands direct to consumer ("D2C")
through its proprietary e-commerce platform across the globe. The
Partner's technology, brand building expertise, and global
infrastructure allows it to reach millions of customers around the
world. They own the largest D2C sports nutrition brand
globally.
LeanBiome (TM) is a scientifically formulated sports nutrition
ingredient which has been developed by OptiBiotix that supports
athletes seeking to increase lean muscle mass to change their body
composition. LeanBiome(TM) contains a patented combination of
fibres, prebiotics and minerals aimed specifically at supporting
the microbiome diversity of athletes on a high protein diet.
LeanBiome(TM) adds unique differentiation to a new premium product
line of the Partner and will get on-pack recognition. The new
product line of the Partner is aimed at increasing lean muscle mass
which is scheduled to be rolled out from January 2022 in Europe and
Asia. If the product line is successful, it is expected to be
introduced to the North American market in due course. The
agreement is expected to generate approximately GBP1m in annualised
and recurring turnover for the Company starting in 2022. First
orders worth GBP200k have been placed and are on schedule for
delivery in early December 2021.
There is growing scientific evidence of an anecdotal link
between the microbiome and athletic performance ( Do microbes
affect athletic performance? (nature.com) .
This agreement is part of OptiBiotix's strategy to offer pro-
and prebiotic solutions aimed at modulating the microbiome that
allow leading brands to differentiate their health & wellness
products.
René Kamminga, C EO of O pti B i oti x Limited, c o mmented :
"We are very pleased to announce this agreement with the Partner
and its sports nutrition division. LeanBiome(TM) has been
specifically formulated with the needs of athletes in mind and
builds on our core expertise in functional ingredients with effect
on the microbiome to achieve health effects. The Partner is a
formidable company to partner with and we are pleased that
LeanBiome -- has been selected as the preferred source of
differentiation for their new product line. This launch is another
important step in building sales and brand presence for OptiBiotix'
solutions with major partners around the world."
This announcement contains information which, prior to its
disclosure, was considered inside information for the purposes of
the UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identiÞed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements reßect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRDBLFXFFLLFBZ
(END) Dow Jones Newswires
December 01, 2021 01:59 ET (06:59 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
